NDAORALTABLET, FOR SUSPENSION
Lifecycle
Pre-Launch
Data completeness
2/8 — Basic
LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE (lamivudine; nevirapine; zidovudine) by PharmaIN is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()]. Approved for hiv-1 infection in adults, weighing at least 6 kg.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
A fixed-dose combination of three HIV-1 antiretroviral agents (lamivudine, nevirapine, and zidovudine) for oral administration. This triple-therapy combination targets HIV-1 infection through nucleoside reverse transcriptase inhibition and non-nucleoside reverse transcriptase inhibition. It is indicated for HIV-1 infection in adults and pediatric patients weighing at least 6 kg.
Pre-Launch
Pre-launch stage suggests limited commercial infrastructure; team buildout and launch planning are active priorities.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications (2)
Worked on LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.